Press Releases

Year

Dec 30, 2019

Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo No difference in total HTT protein or neurofilament light chain in treated patients vs. placebo Additional cohort expected to initiate in January 2020 Wave to host investor

Dec 16, 2019

Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

No change from baseline in dystrophin observed in Phase 1 open-label extension study Wave to host investor conference call at 8:00 a.m. ET today CAMBRIDGE, Mass. , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to

Nov 05, 2019

Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open-label extension study expected in 4Q 2019 Topline data from PRECISION-HD2 clinical trial expected by year-end Key hires and board expansion mark continued progress towards

Sep 16, 2019

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping Clinical dystrophin data from interim analysis of ongoing OLE study on track for 4Q 2019 DYSTANCE 51 global Phase 2/3 trial is underway CAMBRIDGE, Mass.

Sep 06, 2019

Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

Wave leadership to present updates on multiple preclinical programs and discuss advances in PRISM™ platform CAMBRIDGE, Mass. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for

Sep 05, 2019

Wave Life Sciences Expands Board of Directors with Three New Appointments

New independent directors bring deep expertise in drug development, commercial operations and government affairs CAMBRIDGE, Mass. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments

Aug 26, 2019

Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass. , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Aug 06, 2019

Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer

Commercial build-out to support anticipated launch of suvodirsen and other future commercialized products CAMBRIDGE, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for

Jul 29, 2019

Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update

Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated First topline data from PRECISION-HD clinical program expected by year-end CAMBRIDGE, Mass.

Jun 27, 2019

Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping Results intended to support regulatory approvals globally CAMBRIDGE, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Downloads

Investor Inquiries

Email Alerts

Press Releases

Press Releases

About

Science

Pipeline

Careers